Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-401 in pediatric BPDCN
jRCT2011250059Phase 4Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Sep 2026
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tagraxofusp in Blastic plasmacytoid dendritic cell neoplasm (BPDCN), sponsored by Nippon Shinyaku. Primary endpoints: Pharmacokinetics, Immunogenicity and 2 more. Started Sep 2026; status: recruiting.
02
Drugs
tagraxofusp
03
Conditions
Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on jRCT2011250059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250059.